<code id='DFC1F46770'></code><style id='DFC1F46770'></style>
    • <acronym id='DFC1F46770'></acronym>
      <center id='DFC1F46770'><center id='DFC1F46770'><tfoot id='DFC1F46770'></tfoot></center><abbr id='DFC1F46770'><dir id='DFC1F46770'><tfoot id='DFC1F46770'></tfoot><noframes id='DFC1F46770'>

    • <optgroup id='DFC1F46770'><strike id='DFC1F46770'><sup id='DFC1F46770'></sup></strike><code id='DFC1F46770'></code></optgroup>
        1. <b id='DFC1F46770'><label id='DFC1F46770'><select id='DFC1F46770'><dt id='DFC1F46770'><span id='DFC1F46770'></span></dt></select></label></b><u id='DFC1F46770'></u>
          <i id='DFC1F46770'><strike id='DFC1F46770'><tt id='DFC1F46770'><pre id='DFC1F46770'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:73779
          HHS 2020
          PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

          WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

          The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

          advertisement

          PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Albert Bourla of Pfizer: worst biopharma CEO of 2023
          Albert Bourla of Pfizer: worst biopharma CEO of 2023

          HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          CRISPR gene editing developments we’re watching in 2024

          ChristineKao/STATLifeintheCRISPRlanetendstomoveatlightningspeed.Thisyearsawthefirst-everapprovalofam